tolvaptan has been researched along with Down Syndrome in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirano, D; Ito, A; Kakegawa, D; Miwa, S; Takemasa, Y; Tokunaga, A; Umeda, C; Yuhei, K | 1 |
1 other study(ies) available for tolvaptan and Down Syndrome
| Article | Year |
|---|---|
Impact of acute kidney injury in patients prescribed angiotensin-converting enzyme inhibitors over the first two years of life.
Topics: Acute Kidney Injury; Angiotensin-Converting Enzyme Inhibitors; Child; Down Syndrome; Humans; Infant; Infant, Newborn; Male; Renal Insufficiency, Chronic; Retrospective Studies; Risk Factors; Tolvaptan | 2021 |